On June 22, 2023 Starpharma (ASX: SPL, OTCQX: SPHRY) today announces that an investor presentation by Chief Executive Officer, Dr Jackie Fairley, will be broadcast at 10:00 am EDT on Thursday, 22 June 2023 (12:00 am AEST on Friday, 23 June 2023), as part of the OTCQX’s Virtual Life Sciences Investor Forum (Press release, Starpharma, JUN 22, 2023, View Source;mc_eid=bf52dd3418 [SID1234632830]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Life Sciences Investor Forum is a leading, virtual investor conference that provides a forum for public companies to present to retail and institutional investors as well as advisors.
The CEO’s pre-recorded presentation will provide an overview of Starpharma’s business including:
Recent progress across Starpharma’s internal clinical DEP programs including for both the Phase 2 DEP cabazitaxel and DEP docetaxel (monotherapy) trials, which have completed recruitment and treatment of patients, as well as the DEP irinotecan Phase 2 trial.
The latest preclinical results for Starpharma’s HER2-targeted DEP antibody-drug conjugate (ADC), which utilised the active metabolite of irinotecan, SN-38, showed significantly greater anti-tumour activity and improved survival compared to the marketed ADC, Enhertu, in a HER2+ human cancer xenograft model.
An overview of Starpharma’s partnership with AstraZeneca and the clinical development of AZD0466, which utilises Starpharma’s DEP technology to deliver and widen the therapeutic window of a Bcl-2/xL inhibitor and is the subject of two global Phase 1/2 clinical trials recruiting patients with advanced blood cancers at over 40 sites globally.
Regulatory and commercial progress for Starpharma’s in-market products, including Viraleze and VivaGel BV.
The presentation is appended and will also be made available on Starpharma’s website